These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
477 related articles for article (PubMed ID: 19532078)
21. Therapy insight: Body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy. Falutz J Nat Clin Pract Endocrinol Metab; 2007 Sep; 3(9):651-61. PubMed ID: 17710086 [TBL] [Abstract][Full Text] [Related]
22. Risk of cardiovascular disease in a cohort of HIV-infected adults: a study using carotid intima-media thickness and coronary artery calcium score. Mangili A; Gerrior J; Tang AM; O'Leary DH; Polak JK; Schaefer EJ; Gorbach SL; Wanke CA Clin Infect Dis; 2006 Dec; 43(11):1482-9. PubMed ID: 17083026 [TBL] [Abstract][Full Text] [Related]
23. Clinical cardiac manifestations of HIV infection: a review of current literature. Chu WW; Sosman JM; Stein JH WMJ; 2002; 101(7):40-5, 39. PubMed ID: 12426919 [TBL] [Abstract][Full Text] [Related]
24. Antiretroviral therapy in HIV-infected children: the metabolic cost of improved survival. Leonard EG; McComsey GA Infect Dis Clin North Am; 2005 Sep; 19(3):713-29. PubMed ID: 16102657 [TBL] [Abstract][Full Text] [Related]
25. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. Calza L; Manfredi R; Chiodo F J Antimicrob Chemother; 2004 Jan; 53(1):10-4. PubMed ID: 14645323 [TBL] [Abstract][Full Text] [Related]
26. Cardiovascular risk among HIV-positive patients on antiretroviral therapy. Aberg JA J Int Assoc Physicians AIDS Care (Chic); 2003 Sep; 2 Suppl 2():S24-39. PubMed ID: 14569635 [TBL] [Abstract][Full Text] [Related]
27. Human immunodeficiency virus and atherosclerosis. Farrugia PM; Lucariello R; Coppola JT Cardiol Rev; 2009; 17(5):211-5. PubMed ID: 19690471 [TBL] [Abstract][Full Text] [Related]
28. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Savès M; Chêne G; Ducimetière P; Leport C; Le Moal G; Amouyel P; Arveiler D; Ruidavets JB; Reynes J; Bingham A; Raffi F; Clin Infect Dis; 2003 Jul; 37(2):292-8. PubMed ID: 12856222 [TBL] [Abstract][Full Text] [Related]
29. First Italian consensus statement on diagnosis, prevention and treatment of cardiovascular complications in HIV-infected patients in the HAART era (2006). Carosi G; Quiros-Roldan E; Torti C; Antinori A; Bevilacqua M; Bonadonna RC; Bonfanti P; Castagna A; Cauda R; d'Arminio-Monforte A; Di Gregorio P; Di Perri G; Esposito R; Fatuzzo F; Gervasoni C; Giannattasio C; Guaraldi G; Lazzarin A; Lo Caputo S; Maggi P; Mazzotta F; Moroni M; Prestileo T; Ranieri R; Rizzardini G; Russo R; Galli M; Infection; 2007 Jun; 35(3):134-42. PubMed ID: 17565453 [TBL] [Abstract][Full Text] [Related]
30. Cardiovascular disease and therapeutic drug-related cardiovascular consequences in HIV-infected patients. Fisher SD; Kanda BS; Miller TL; Lipshultz SE Am J Cardiovasc Drugs; 2011 Dec; 11(6):383-94. PubMed ID: 22149317 [TBL] [Abstract][Full Text] [Related]
31. Risks of cardiovascular disease in patients receiving antiretroviral therapy for HIV infection: implications for treatment. Steinhart CR; Emons MF AIDS Read; 2004 Feb; 14(2):86-90, 93-5. PubMed ID: 14997864 [TBL] [Abstract][Full Text] [Related]
32. Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study. Glass TR; Ungsedhapand C; Wolbers M; Weber R; Vernazza PL; Rickenbach M; Furrer H; Bernasconi E; Cavassini M; Hirschel B; Battegay M; Bucher HC; HIV Med; 2006 Sep; 7(6):404-10. PubMed ID: 16903986 [TBL] [Abstract][Full Text] [Related]
33. Diagnosis and management of body morphology changes and lipid abnormalities associated with HIV Infection and its therapies. Wohl DA Top HIV Med; 2004; 12(3):89-93. PubMed ID: 15310940 [TBL] [Abstract][Full Text] [Related]
34. HAART to heart: highly active antiretroviral therapy and the risk of cardiovascular disease in HIV-infected or exposed children and adults. Lipshultz SE; Mas CM; Henkel JM; Franco VI; Fisher SD; Miller TL Expert Rev Anti Infect Ther; 2012 Jun; 10(6):661-74. PubMed ID: 22734956 [TBL] [Abstract][Full Text] [Related]
36. [Controversies and future of the approach to cardiovascular disease in HIV patients]. Bernardino de la Serna JI; Arribas López JR Enferm Infecc Microbiol Clin; 2009 Sep; 27 Suppl 1():48-53. PubMed ID: 20172415 [TBL] [Abstract][Full Text] [Related]
37. Cardiovascular risk factors and probability for cardiovascular events in HIV-infected patients. Part II: gender differences. Neumann T; Woiwod T; Neumann A; Ross B; Von Birgelen C; Volbracht L; Brockmeyer NH; Gerken G; Erbel R Eur J Med Res; 2004 Feb; 9(2):55-60. PubMed ID: 15090290 [TBL] [Abstract][Full Text] [Related]
38. N-terminal pro-B-type natriuretic peptide (NT-proBNP) in HIV-1 infected individuals on HAART. Berg T; Zdunek D; Stalke J; Dupke S; Baumgarten A; Carganico A; Hess G Eur J Med Res; 2007 Apr; 12(4):152-60. PubMed ID: 17509959 [TBL] [Abstract][Full Text] [Related]
39. Cardiovascular risk and risk management in HIV-infected patients. Adeyemi O Top HIV Med; 2007; 15(5):159-62. PubMed ID: 18073451 [TBL] [Abstract][Full Text] [Related]
40. A comparison of the predicted risk for cardiovascular disease between HIV-infected and uninfected persons in Korea. Kim SB; Kim YC; Kim MH; Song JE; Oh DH; Ahn JY; Ku NS; Kim HW; Jeong SJ; Han SH; Song YG; Choi JY; Kim JM Scand J Infect Dis; 2013 Nov; 45(11):855-62. PubMed ID: 23968223 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]